Compound 5

(2Z,2'E)-Dimethyl 2,2'-((1S,3S,7R,11S,12S,15S,17R,21R,23S,E)-11,21-dihydroxy-17-(hydroxymethyl)-10,10,26,26-tetramethyl-12-(octanoyloxy)-19-oxo-18,27,28,29-tetraoxatetracyclo[21.3.1.13,7.111,15]nonacos-8-ene-5,13-diylidene)diacetate

From: Designed, synthetically accessible bryostatin analogues potently induce activation of latent HIV reservoirs in vitro

View in PubChem | MDL Molfile | ChemDraw

InChIKey PJNIHQVUSONDAR-KTRVGUEHSA-N

Synthetic procedure: See article for the definitive version of this procedure and for full experimental details.

In a 15 mL polypropylene vial, enoate mixture 26 (8.1 mg, ca 0.0069 mmol) was dissolved in THF (6.2 mL) under N2 atmosphere. This solution was cooled in a CO2/acetone bath for 10 min, at which time 70% HF·pyridine (1.55 mL) was added dropwise over 1 min. The reaction vessel was allowed to stir at -78°C for 10 more min, at which time the reaction vessel was removed from the cold bath and allowed to warm to ambient temperature. After stirring 90 h, the reaction mixture was quenched into saturated aqueous NaHCO3 (50 mL). The resulting mixture was diluted with water (15 mL) and Et2O (30 mL). The layers were separated, and the aqueous layer was extracted with EtOAc (3 × 25 mL). The combined organic phase was dried over Na2SO4, filtered, and concentrated. The resulting oil was purified via silica gel column chromatography (45→50% EtOAc:Pentane) to afford 4.5 mg (79%) as a mixture of enoate analogues 5 (Z-enoate) and C13-C30 geometric isomer S5 (E-enoate). This mixture was separated via preparative reverse-phase C18 chromatography (65% MeCN→100% MeCN in H2O over 30 minutes) to afford 2.2 mg analogue 5 (38%) and 1.1 mg C13-C30 geometric isomer S5 (19%). 1H NMR (CDCl3, 500 MHz): δ 5.99 (d, J = 1.7 Hz, 1H, C27), 5.74 (d, J = 15.9 Hz, 1H, C17), 5.67 (s, 1H, C30), 5.35 (m, 1H, C25), 5.33 (dd, J = 8.3, 15.9 Hz, 1H, C16), 5.18 (s, 1H, C19-OH), 5.13 (s, 1H, C20), 4.96 (d, J = 11.7 Hz, 1H, C3-OH), 4.22 (m, 1H, C3), 4.06 (tt, J = 2.2, 11.2 Hz, 1H, C23), 3.97 (ddd, J = 2.2, 8.3, 10.7 Hz, 1H, C15), 3.84 (dt, J = 3.9, 12.0 Hz, 1H, C26), 3.68-3.75 (m, 1H, C22), 3.70 (s, 3H, -OMe), 3.68 (s, 3H, -OMe), 3.60-3.66 (m, 2H, C14, C26), 3.55 (ddd, J = 2.7, 6.4, 10.7 Hz, 1H, C11), 3.49 (bt, J = 11.2 Hz, 1H, C5), 3.13 (dd, J = 1.7, 11.5 Hz, 1H, C9), 2.40-2.49 (m, 2H, C2, C2), 2.25-2.35 (m, 2H, C31), 2.08-2.23 (m, 2H, C12, C12), 1.92-2.08 (m, 4H, C4, C22, C24, C26-OH), 1.89 (bt, J = 12.7 Hz, 1H, C14), 1.79 (ddd, J = 2.7, 11.7, 13.7 Hz, 1H, C24), 1.70 (ddd, J = 6.6, 11.7, 15.4 Hz, 1H, C10), 1.62 (m, 2H, C32), 1.41-1.53 (m, 3H, C4, C6, C10), 1.21-1.38 (m, 11H, C6, C7, C7, C33-C36), 1.15 (s, 3H, C28), 1.01 (s, 3H, C29), 0.88 (t, J = 6.8 Hz, 3H, C37), 0.86 (s, 3H, C(8)(CH3)2), 0.81 (s, 3H, C(8)(CH3)), ppm. 13C NMR (CDCl3, 125 MHz): δ 172.5, 172.3, 167.2, 166.9, 157.0, 152.0, 138.6, 130.0, 119.9, 114.4, 99.0, 86.2, 79.0, 76.2, 74.4, 71.6, 68.8, 65.9, 64.6, 51.2, 51.2, 45.0, 44.2, 43.0, 40.3, 39.0, 37.0, 36.6, 36.0, 34.8, 32.4, 31.8, 31.2, 29.2, 29.0, 29.0, 27.8, 24.8, 24.7, 22.7, 19.9, 19.4, 14.2 ppm. IR (film) 3458, 3338, 2930, 2851, 1721, 1658, 1434, 1407, 1378, 1282, 1258, 1226, 1160, 1099, 1084, 1046, 1004, 877, 807 cm−1. HRMS (TOF MS ES+): Calculated for C44H68O14Na+: 843.4507; Found: 843.4501. [α]D23.7 = 21.47° (c = 0.22, CHCl3). Rf = 0.44 (60%% EtOAc , 40% Petroleum ether) – one black spot (p-anisaldehyde stain).